Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Inc. - Warrant (NQ:TVGNW)

0.0875 +0.0135 (+18.24%)
Delayed Quote Updated: 3:57 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Inc. - Warrant

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Reports First Quarter 2024 Financial Results
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.